Oversulfated chondroitin sulfate (OSCS) has become the subject of multidisciplinary investigation as a non-traditional contaminant in the heparin therapeutic preparations that were linked to severe adverse events. In this study, it was found that OSCS inhibited complement fixation on bacteria and bacterial lysis mediated by the complement classical pathway. The inhibition of complement by OSCS is not due to interference with antibody/antigen interaction or due to consumption of C3 associated with FXII-dependent contact system activation. However, OSCS complement inhibition is dependent on C1 inhibitor (C1inh) since the depletion of C1inh from either normal or FXII-deficient complement plasma prevents OSCS inhibition of complement activity. Surface plasmon resonance measurements revealed that immobilized C1inhibitor bound greater than 5-fold more C1s in the presence of OSCS than in presence of heparin. Although heparin can also inhibit complement, OSCS and OSCS contaminated heparin are more potent inhibitors of complement. Furthermore, polysulfated glycosaminoglycan (PSGAG), an anti-inflammatory veterinary medicine with a similar structure to OSCS, also inhibited complement in the plasma of dogs and farm animals. This study provides a new insight that in addition to the FXII-dependent activation of contact system, oversulfated and polysulfated chondroitin-sulfate can inhibit complement activity by potentiating the classical complement pathway regulator C1inh. This effect on C1inh may play a role in inhibiting inflammation as well as impacting bacterial clearance.
References
[1]
Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, et al. (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358: 2457–2467.
[2]
Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, et al. (2008) Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 359: 2674–2684.
[3]
Adam A, Montpas N, Keire D, Desormeaux A, Brown NJ, et al. (2010) Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 31: 5741–5748.
[4]
Li B, Suwan J, Martin JG, Zhang F, Zhang Z, et al. (2009) Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol 78: 292–300.
[5]
Muller-Eberhard HJ (1975) Complement. Annu Rev Biochem 44: 697–724.
[6]
Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785–797.
[7]
Martinez-Barricarte R, Heurich M, Valdes-Canedo F, Vazquez-Martul E, Torreira E, et al. (2010) Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120: 3702–3712.
[8]
Pangburn MK, Muller-Eberhard HJ (1983) Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann N Y Acad Sci 421: 291–298.
[9]
Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH (2010) Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 215: 1–11.
[10]
Matsushita M (2010) Ficolins: complement-activating lectins involved in innate immunity. J Innate Immun 2: 24–32.
[11]
Kirschfink M, Mollnes TE (2003) Modern complement analysis. Clin Diagn Lab Immunol 10: 982–989.
[12]
Bohlson SS, Strasser JA, Bower JJ, Schorey JS (2001) Role of complement in Mycobacterium avium pathogenesis: in vivo and in vitro analyses of the host response to infection in the absence of complement component C3. Infect Immun 69: 7729–7735.
[13]
Janeway Jr CA, Travers P, Walport M, Shlomchik MJ (2001) The complement system and innate immunity. Immunobiology: The Immune System in Health and Disease. 5 ed. New York: Garland Science.
[14]
Okroj M, Heinegard D, Holmdahl R, Blom AM (2007) Rheumatoid arthritis and the complement system. Ann Med 39: 517–530.
[15]
Chesne S, Villiers CL, Arlaud GJ, Lacroix MB, Colomb MG (1982) Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1. Biochem J 201: 61–70.
[16]
Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, et al. (2007) The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 1: 51–61.
[17]
Hirsh J, Dalen JE, Deykin D, Poller L (1992) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 102: 337S–351S.
[18]
Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, et al. (1997) Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 159: 1953–1960.
[19]
Maillet F, Petitou M, Choay J, Kazatchkine MD (1988) Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol Immunol 25: 917–923.
[20]
Caughman GB, Boackle RJ, Vesely J (1982) A postulated mechanism for heparin's potentiation of C1 inhibitor function. Mol Immunol 19: 287–295.
[21]
Zhang Z, Weiwer M, Li B, Kemp MM, Daman TH, et al. (2008) Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 51: 5498–5501.
[22]
Jaskowski TD, Martins TB, Litwin CM, Hill HR (1999) Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol 6: 137–139.
[23]
Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54: 570–575.
[24]
Zhou ZH, Chen T, Arora K, Hyams K, Kozlowski S (2012) Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events. PLoS One 7: e34978.
[25]
Beinrohr L, Harmat V, Dobo J, Lorincz Z, Gal P, et al. (2007) C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 282: 21100–21109.
[26]
Rajabi M, Struble E, Zhou Z, Karnaukhova E (2012) Potentiation of C1-esterase inhibitor by heparin and interactions with C1s protease as assessed by surface plasmon resonance. Biochim Biophys Acta 1820: 56–63.
[27]
King CS, Holley AB, Jackson JL, Shorr AF, Moores LK (2007) Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest 131: 507–516.
[28]
de Messias IT, Mohren D, Kajdacsy-Balla A (1994) Inhibition of the classical and alternative pathways of the human complement system by glycosaminoglycan polysulfate. J Investig Allergol Clin Immunol 4: 172–176.
[29]
Jiang H, Wagner E, Zhang H, Frank MM (2001) Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 194: 1609–1616.
[30]
Gustafson SB, McIlwraith CW, Jones RL (1989) Comparison of the effect of polysulfated glycosaminoglycan, corticosteroids, and sodium hyaluronate in the potentiation of a subinfective dose of Staphylococcus aureus in the midcarpal joint of horses. Am J Vet Res 50: 2014–2017.
[31]
Gustafson SB, McIlwraith CW, Jones RL, Dixon-White HE (1989) Further investigations into the potentiation of infection by intra-articular injection of polysulfated glycosaminoglycan and the effect of filtration and intra-articular injection of amikacin. Am J Vet Res 50: 2018–2022.
[32]
Makrides SC (1998) Therapeutic inhibition of the complement system. Pharmacol Rev 50: 59–87.
[33]
Girardi G, Redecha P, Salmon JE (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 10: 1222–1226.
[34]
Tami C, Puig M, Reepmeyer JC, Ye H, D'Avignon DA, et al. (2008) Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 29: 4808–4814.
[35]
Myszka DG, Morton TA (1998) CLAMP: a biosensor kinetic data analysis program. Trends Biochem Sci 23: 149–150.
